BiotechTube

VB10.2129 + VB10.2210

Phase 1/2Completed
2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19, Infection Viral, Infections

Trial Timeline

Nov 1, 2021 → May 30, 2023

NCT ID
NCT05069623

About VB10.2129 + VB10.2210

VB10.2129 + VB10.2210 is a phase 1/2 stage product being developed by Nykode Therapeutics for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT05069623. Target conditions include COVID-19, Infection Viral, Infections.

What happened to similar drugs?

7 of 20 similar drugs in COVID-19 were approved

Approved (7) Terminated (4) Active (11)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅Rivaroxaban 10 mgBayerApproved
✅Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)NovavaxApproved
✅protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineNovavaxApproved
✅NVX-CoV2705 + PlaceboNovavaxApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05069623Phase 1/2Completed

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
InfliximabCelltrionPhase 2
35
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
32
Enzalutamide PillAstellas PharmaPhase 2
27
S-892216 + PlaceboShionogiPhase 2
35
S-892216 + CarbamazepineShionogiPhase 1
29
FOY-305 + PlaceboOno PharmaceuticalPhase 3
40
DesidustatZydus LifesciencesPhase 2
35
LY3819253 + PlaceboEli LillyPhase 1
29